---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010756"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:05:59.430938+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Syndax appoints Neil Gallagher as President, Head of R&D; Morrison transitions

## Summary
- Neil Gallagher, M.D., Ph.D., appointed President, Head of R&D effective April 10, 2023; previously CMO at AbbVie.
- Briggs Morrison resigns as President, Head of R&D effective April 15, 2023; will consult for 3 months, remains on board.
- Gallagher receives $530k base salary, 45% target bonus, and inducement option for 250k shares vesting over 4 years.
- Company expects to advance revumenib and axatilimab through pivotal data and regulatory filings in 2023.

## SEC filing metadata
- accession: 0000950170-23-010756
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/0000950170-23-010756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/sndx-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010756
- JSON: https://secwatch.observer/filing/0000950170-23-010756.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010756.txt

## Key facts
- Executive change
  Briggs W. Morrison resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.
  - Action: resigned
  - Role: President, Head of Research and Development
  source text: On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/0000950170-23-010756-index.htm
- Executive change
  Neil Gallagher was appointed as President, Head of Research and Development at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: President, Head of Research and Development
  source text: On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023010756/0000950170-23-010756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.